CLClinicLens

Infectious Disease

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis. | ClinicLens

Safer, more effective treatment regimens for rifampicin-resistant tuberculosis are needed. We conducted a phase 3, open-label, pragmatic, randomized, controlled noninferiority trial in South Africa to assess a 6-month treatment strategy for pulmonary rifampicin-resistant tubercul

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.